News

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...
Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...
A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on ...
While your baby may not have made his big entrance yet, it's important to understand the recommended vaccines and schedule now. That's because your child’s immunizations will play a major role during ...
FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.
Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...
The diagnosis was confirmed through rapid testing after the Coconino County resident was admitted to Flagstaff Medical Center. Pneumonic plague is the only form of the plague that can be transmitted ...
GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the ...
Two new studies demonstrate the impact of respiratory syncytial virus (RSV) in different populations, with one showing that ...
The CDC already recommends the RSV shot for all adults 75 and older and for people 60 and older who have health conditions that increase their risk of severe RSV. It also recommends the shot during ...